Clinical NRx Pharmaceuticals signs deal for clinical trials of Israel's...

NRx Pharmaceuticals signs deal for clinical trials of Israel’s homegrown Covid-19 vaccine


Israel Institute for Biological Research (IIBR), an institute run by Israel’s Defense Ministry, has signed a memorandum of understanding (MoU) with the NRx Pharmaceuticals. According to which Israel’s domestic COVID-19 vaccine will undergo clinical trials as revealed by a statement.

Brilife, the said vaccine, will be driven to complete its third-stage clinical trials by the NRx Pharmaceuticals. Tens of thousands of volunteers belonging to Ukraine, Georgia and Israel will take part for the said cause after which the company will work up the commercialization of the vaccine. The Israeli vaccine is currently undergoing its second-stage trials after the fruitful attainment of first one in December, 2020 by IIBR.

The Defense Minister of Israel, Benny Gantz, applauded this covenant considering it “an excellent news”. In one of his statements Gantz narrates, “I anticipate that with this agreement, we will be able to complete the development of the vaccine and enable Israel to produce vaccines independently, because as we have seen recently – the coronavirus is not going anywhere”.

+ posts

Latest news

Novo Nordisk Set to Slash Victoza Production to Boost Ozempic Supply

In response to the escalating demand for its GLP-1 weight loss products, Novo Nordisk is adopting a...

Merck to Purchase Caraway Therapeutics For Over $600M

Merck & Co. has openly expressed its continuous pursuit of acquisitions, and currently, the prominent pharmaceutical company...

NanoString Faces Setback in Patent Infringement Case Against Genomics

In a recent legal skirmish in the biotechnology sector, NanoString finds itself on the losing end of...

Must read

Surrounded by controversy, FDA approves Biogen’s Alzheimer’s drug Aduhelm

In the middle of the debate about the Alzheimer’s drug approval, the United States FDA has authorized Aduhelm

You might also likeRELATED
Recommended to you